Safety and efficacy of concurrent carboplatin or cetuximab chemoradiation in cisplatin ineligible locally advanced head and neck squamous cell carcinoma

被引：0
|
作者：
Marinho, Joana [1 ]
Laranja, Andre [2 ]
Leao, Ines [1 ]
Joaquim, Ana [1 ]
Vieira, Claudia [3 ]
Dinis, Jose [3 ]
Soares, Andre [2 ]
Moreira, Diana [2 ]
机构：
[1] Ctr Hosp Vila Nova de Gaia Espinho, Med Oncol Dept, Vila Nova De Gaia, Portugal
[2] Inst Portugues Oncol Porto, Radiat Oncol Dept, Porto, Portugal
[3] Inst Portugues Oncol Porto, Med Oncol Dept, Porto, Portugal
来源：
ORAL ONCOLOGY | 2021年 / 118卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-188
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck
    Levy, Adrian R.
    Johnston, Karissa M.
    Sambrook, Jennifer
    Donato, Bonnie
    Penrod, John R.
    Corral, Mitra
    Chasen, Martin
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (12) : 2253 - 2259
  • [32] Toxicity of Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma Treatment
    Torres, S.
    Sargento, I.
    Ferreira, M.
    Oliveira, J. O. A. O.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S552 - S552
  • [33] Gemcitabine versus cisplatin concurrent with radiation therapy in locally advanced head and neck squamous cell carcinoma
    Mostafa, Magda
    Atif, Hesham
    Fawzy, Mahmoud
    Sakr, Amr Yehia
    Alashwah, Ahmed
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Carboplatin-Based Chemoradiation Improves Outcomes Compared to Cetuximab Bioradiation in Cisplatin Ineligible Locally Advanced p16 Negative Head and Neck cancer
    Barney, C.
    Branstetter, A.
    Yaney, A.
    Healy, E.
    Rupert, R.
    Neki, A.
    Walston, S. A., Jr.
    Diavolitsis, V. M.
    Blakaj, D. M.
    Wobb, J. L.
    Mitchell, D. L.
    Grecula, J. C.
    Savvides, P.
    Bhatt, A. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1327 - 1328
  • [35] Mono centric experience of concurrent Radiotherapy and Cetuximab in the treatment of locally advanced squamous cell carcinoma of the head and neck
    Roman, J.
    Miglierini, P.
    Le Fur, E.
    Miranda, O.
    Pradier, O.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 : 100 - 100
  • [36] Efficacy and safety of concurrent chemoradiotherapy (CCR) for unresectable locally advanced (ULA) head and neck squamous cell carcinoma (HNSCC).
    Castro, G
    Snitcovsky, IML
    Gebrim, EM
    Leitao, GM
    Rocha, CN
    Nadalin, W
    Ferraz, AR
    Federico, MHH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 522S - 522S
  • [37] Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma
    Goshi Nishimura
    Takahide Taguchi
    Masahiro Takahashi
    Osamu Shiono
    Masanori Komatsu
    Daisuke Sano
    Kenichiro Yabuki
    Yasuhiro Arai
    Hideaki Takahashi
    Masaharu Hata
    Nobuhiko Oridate
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1315 - 1319
  • [38] Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma
    Nishimura, Goshi
    Taguchi, Takahide
    Takahashi, Masahiro
    Shiono, Osamu
    Komatsu, Masanori
    Sano, Daisuke
    Yabuki, Kenichiro
    Arai, Yasuhiro
    Takahashi, Hideaki
    Hata, Masaharu
    Oridate, Nobuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1315 - 1319
  • [39] Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review
    Michelon, Isabella
    Nachtigal, Gilca Costa
    Dacoregio, Maria Inez
    Moraes, Ana Cristina Beitia Kraemer
    Moraes, Mauricio
    Piva, Livia Silva
    da Costa, Catiara Terra
    Lund, Rafael Guerra
    Michelon, Douver
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (08)
  • [40] Single institute analysis of squamous cell carcinoma of the head and neck treated with concurrent chemoradiation with either cisplatin versus cetuximab.
    Jeong, Il Seok
    Kim, Matthew
    Nguyen, Anthony L.
    Mo, Huan
    Hayton, Bruce
    Xu, David
    Huynh Le Cao
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345